{"schema_version":"secwatch.filing_event.v1","accession":"0001411685-25-000017","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.558848+00:00","generated_at":"2026-05-26T22:11:34.080806+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vistagen reports Q3 FY2025 net loss $14.1M; fasedienol Phase 3 progressing","bullets":["Net loss $14.1M for Q3 ended Dec 31, 2024, vs $6.4M YoY; R&D expense rose to $11.3M from $4.5M.","Cash and marketable securities $88.6M as of Dec 31, 2024.","Fasedienol PALISADE-3 and PALISADE-4 Phase 3 trials for SAD ongoing; top-line results expected later 2025.","Positive exploratory Phase 2A results for PH284 in cancer cachexia announced.","IND-enabling program for PH80 for menopausal hot flashes continuing; Phase 2B planning for itruvone in MDD."],"urls":{"canonical":"https://secwatch.observer/filing/0001411685-25-000017","json":"https://secwatch.observer/filing/0001411685-25-000017.json","markdown":"https://secwatch.observer/filing/0001411685-25-000017.md","text":"https://secwatch.observer/filing/0001411685-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000017/0001411685-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000141168525000017/vtgn-20250213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:11:34.080806+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}